In recent weeks, Pfizer has said it should know by the end of October whether the vaccine, developed together with Germany’s BioNTech SE, is safe and effective. If the vaccine is shown to work by then, Pfizer has said it would quickly seek regulatory approval. Pfizer’s clinical trial protocol outlines for the company, scientists and regulators how the drugmaker could show that its vaccine meets efficacy and safety standards set by the U.S. Food and Drug Administration.
